Literature DB >> 7640865

Formation of porcine hepatocyte spheroids for use in a bioartificial liver.

A Lazar1, M V Peshwa, F J Wu, C M Chi, F B Cerra, W S Hu.   

Abstract

Xenogeneic hepatocytes have recently been used in a bioartificial liver device as a potential short-term extracorporeal support of acute liver failure. Scaling up the system requires large quantities of viable and highly active cells. Hepatocytes grown as spheroids manifest higher metabolic activities for longer time periods as compared to those in monolayer cultures. Use of hepatocyte spheroids for application in a bioartificial liver can possibly alleviate the need of scaling up. Porcine hepatocytes when cultured under stirred conditions, from multicellular spheroids in a defined culture medium. Spheroids were formed 24 h after cell inoculation with an efficiency of 80-90% and a mean diameter of about 135 microns. Scanning electron microscopy revealed numerous microvilli projecting from the entire surface of the spheroids. Transmission electron microscopy revealed differentiated hepatocytes which displayed well-developed cytoplasmic structures separated by bile canaliculus-like structures. The morphological studies show a resemblance between cells in the spheroids and in the liver in vivo. Urea-genesis by spheroids was twice as active and was sustained for a longer culture period than that by hepatocytes cultured as monolayers. Preparation of porcine hepatocyte spheroids in an agitated vessel is simple efficient and reproducible. It will allow for preparation of large quantities of spheroids to be employed in a bioartificial liver device as well as in liver metabolism studies.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7640865     DOI: 10.1177/096368979500400303

Source DB:  PubMed          Journal:  Cell Transplant        ISSN: 0963-6897            Impact factor:   4.139


  9 in total

1.  In vitro culture of rat hepatocytes without exogenous matrix.

Authors:  M Barbich; A Lorenti; P Sorroche; E Mocetti; A Hidalgo; C B de Di Risio; S H Hyon; P Argibay
Journal:  In Vitro Cell Dev Biol Anim       Date:  2000 Jul-Aug       Impact factor: 2.416

2.  Rational bioprocess design for human pluripotent stem cell expansion and endoderm differentiation based on cellular dynamics.

Authors:  Mark D Ungrin; Geoff Clarke; Ting Yin; Sylvia Niebrugge; M Cristina Nostro; Farida Sarangi; Geoffrey Wood; Gordon Keller; Peter W Zandstra
Journal:  Biotechnol Bioeng       Date:  2011-12-02       Impact factor: 4.530

3.  Development of a bioartificial liver employing xenogeneic hepatocytes.

Authors:  W S Hu; J R Friend; F J Wu; T Sielaff; M V Peshwa; A Lazar; S L Nyberg; R P Remmel; F B Cerra
Journal:  Cytotechnology       Date:  1997-01       Impact factor: 2.058

4.  Engineering analysis and development of the spheroid reservoir bioartificial liver.

Authors:  Malcolm B McIntosh; Stephen M Corner; Bruce P Amiot; Scott L Nyberg
Journal:  Conf Proc IEEE Eng Med Biol Soc       Date:  2009

5.  Functional evaluation of a new bioartificial liver system in vitro and in vitro.

Authors:  Zhong Chen; Yi-Tao Ding
Journal:  World J Gastroenterol       Date:  2006-02-28       Impact factor: 5.742

6.  Aggregate Size Optimization in Microwells for Suspension-based Cardiac Differentiation of Human Pluripotent Stem Cells.

Authors:  Celine L Bauwens; Derek Toms; Mark Ungrin
Journal:  J Vis Exp       Date:  2016-09-25       Impact factor: 1.355

7.  Hepatic tissue engineering using scaffolds: state of the art.

Authors:  Somaieh Kazemnejad
Journal:  Avicenna J Med Biotechnol       Date:  2009-10

8.  Cell encapsulation in sub-mm sized gel modules using replica molding.

Authors:  Alison P McGuigan; Derek A Bruzewicz; Ana Glavan; Manish J Butte; Manish Butte; George M Whitesides
Journal:  PLoS One       Date:  2008-05-21       Impact factor: 3.240

9.  Profiling the impact of medium formulation on morphology and functionality of primary hepatocytes in vitro.

Authors:  Leonard J Nelson; Philipp Treskes; A Forbes Howie; Simon W Walker; Peter C Hayes; John N Plevris
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.